NCT00905515View on ClinicalTrials.gov

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Kidney Transplantation
Interventions
DRUG

cyclosporine

Maintain on cyclosporine at target trough level of 50-250 ng/mL.

DRUG

Prograf (Tacrolimus)

Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).

Trial Locations (1)

27834

Brody School of Medicine at East Carolina University, Greenville

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

East Carolina University

OTHER

NCT00905515 - Optima: Optimizing Prograf Therapy in Maintenance Allografts II | Biotech Hunter | Biotech Hunter